Fibrinogen Level Assay Service

Online Inquiry

Background Service Highlights FAQs Contact Us

The Needs of Fibrinogen Level Assays for CART Development

Chimeric Antigen Receptor (CAR) T-cell therapy represents a paradigm shift in the treatment of hematological malignancies, offering unprecedented remission rates in patients with relapsed or refractory disease. This innovative immunotherapy engineers a patient's own T-cells to recognize and eliminate cancer cells. However, the potent immune activation triggered by CAR-T cells can lead to unique and potentially life-threatening toxicities. Among these, Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) are the most prominent.

During severe CRS, fibrinogen levels can plummet due to a combination of factors including consumption, hemodilution, and potentially decreased hepatic synthesis secondary to inflammatory cytokine effects. The imperative to meticulously monitor and proactively manage these toxicities is paramount to ensuring patient safety and optimizing the therapeutic efficacy of CAR-T cell therapy. In this context, the accurate and timely assessment of fibrinogen levels through dedicated assays has emerged as an indispensable tool.

Comprehensive Fibrinogen Assay Solutions at Creative Biolabs

As pioneers in CART development solutions, Creative Biolabs recognizes the critical need for robust assays that aid clinicians in navigating the complexities of CAR-T cell therapy. Our portfolio of fibrinogen level assay solutions is specifically designed to meet the demanding requirements of this cutting-edge therapeutic modality.

Our Service Content Includes:

High-Sensitivity Fibrinogen Assays

Creative Biolabs offers state-of-the-art fibrinogen assays, including Clauss methodology-based tests, renowned for their accuracy and reliability in quantifying functional fibrinogen levels, even at critically low concentrations often encountered during severe CRS.

Comprehensive Coagulation Panels

Beyond standalone fibrinogen assays, Creative Biolabs provides comprehensive coagulation panels that include Prothrombin Time (PT/INR), Activated Partial Thromboplastin Time (aPTT), and D-dimer levels. This holistic view is crucial, as studies have indicated that some patients may also experience prolongations in PT and aPTT, further compounding bleeding risks.

Expert Consultation and Support

With over two decades of experience in hematological diagnostics, Creative Biolabs’s team of scientific experts is available to provide consultation on assay selection, result interpretation, and integration into CAR-T toxicity management protocols. We partner with clinical teams to ensure our services align seamlessly with their patient care pathways.

Quality Assurance and Regulatory Compliance

All assays offered by Creative Biolabs are performed under stringent quality control measures, adhering to the highest industry standards and regulatory requirements, ensuring the reliability and reproducibility of results.

Our Advantages

Choosing Creative Biolabs as your partner for fibrinogen level assays and coagulation monitoring in the CAR-T setting offers several distinct advantages, rooted in our long-standing commitment to diagnostic excellence and innovation.

Unparalleled Experience
Cutting-Edge Technology
Focus on CAR-T Specific Needs
Collaborative Partnerships
Robust Quality Management Systems

FAQs

Q1: Why is monitoring fibrinogen levels so critical during CAR-T cell therapy?

A1: Fibrinogen is essential for blood clotting. During Cytokine Release Syndrome (CRS), a common and serious toxicity of CAR-T therapy, fibrinogen levels can drop dangerously low (hypofibrinogenemia). This significantly increases the risk of severe bleeding. Monitoring allows for early detection and intervention, such as fibrinogen replacement, to prevent potentially life-threatening hemorrhagic events. As research indicates, CRS-associated coagulopathy with hypofibrinogenemia is a manageable condition when guided by appropriate monitoring and empiric fibrinogen replacement.

Q2: Can Creative Biolabs' fibrinogen assay help in predicting the severity of CRS or other CAR-T toxicities?

A2: While the primary utility of fibrinogen assays in the CAR-T setting is to monitor and manage coagulopathy, a rapid or profound decrease in fibrinogen levels often correlates with the severity of CRS. It serves as an important indicator of systemic inflammation and endothelial dysfunction. Creative Biolabs is actively involved in research exploring the broader prognostic and predictive utility of coagulation markers, including fibrinogen, in the context of CAR-T cell therapy outcomes and toxicities.

Q3: Are other coagulation tests important to monitor alongside fibrinogen in CAR-T patients?

A3: Yes, a comprehensive assessment of hemostasis is often beneficial. Tests such as Prothrombin Time (PT/INR), Activated Partial Thromboplastin Time (aPTT), and D-dimer can provide additional valuable information. For instance, prolongations in PT and aPTT can also occur in some patients with CRS, further increasing bleeding risk, and elevated D-dimer levels can indicate ongoing fibrinolysis or a prothrombotic state. Creative Biolabs offers comprehensive coagulation panels to address this need.

Contact Us

For more information about Creative Biolabs' fibrinogen level assays, comprehensive coagulation panels, or to discuss how our diagnostic solutions can support your CAR-T cell therapy program, please do not hesitate to contact us. Our team of experts is ready to assist you with your specific needs and explore collaborative opportunities. Reach out to Creative Biolabs today to learn how we can partner to enhance patient care and advance the frontiers of immunotherapy.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.